HomeMPSYF • OTCMKTS
add
Morphosys Ord Shs
Previous close
$73.27
Year range
$20.15 - $73.27
Market cap
2.77B USD
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 34.64M | -34.84% |
Operating expense | 78.93M | -17.78% |
Net income | -79.19M | -7.07% |
Net profit margin | -228.59 | -64.30% |
Earnings per share | — | — |
EBITDA | -44.38M | 6.70% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 512.31M | -23.74% |
Total assets | 1.71B | -20.42% |
Total liabilities | 2.04B | -3.37% |
Total equity | -334.72M | — |
Shares outstanding | 37.66M | — |
Price to book | -8.24 | — |
Return on assets | -6.44% | — |
Return on capital | -7.90% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -79.19M | -7.07% |
Cash from operations | -131.32M | -4.25% |
Cash from investing | 116.76M | 402.25% |
Cash from financing | -2.98M | 36.22% |
Net change in cash | 2.41M | 102.25% |
Free cash flow | 395.49M | 464.18% |
About
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG was listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Founded
1992
Headquarters
Website
Employees
446
